<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378143</url>
  </required_header>
  <id_info>
    <org_study_id>OP-103-C</org_study_id>
    <nct_id>NCT01378143</nct_id>
  </id_info>
  <brief_title>Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy</brief_title>
  <official_title>A Phase II Clinical Study Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (mFOLFOX6 or FOLFIRI) as Second-Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncozyme Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncozyme Pharma Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS&#xD;
      in combination with standard of care as a second line treatment in subjects with unresectable&#xD;
      and locally recurrent or metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, open label study to investigate the safety and efficacy of the use of&#xD;
      OCZ103-OS in combination with standard therapy (mFOLFOX6 or FOLFIRI) as a second line&#xD;
      treatment in subjects with unresectable and locally recurrent or metastatic colorectal&#xD;
      cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor size (CT scan)</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the antitumor activity of OCZ103-OS in combination with standard of care in subjects with unresectable and locally recurrent or metastatic colorectal cancer in terms of tumor growth during treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the antitumor activity of OCZ103-OS in combination with standard of care in subjects with unresectable and locally recurrent or metastatic colorectal cancer in terms of progression free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the antitumor activity of OCZ103-OS in combination with standard of care in subjects with unresectable and locally recurrent or metastatic colorectal cancer in terms of overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of OCZ103-OS</measure>
    <time_frame>2 months</time_frame>
    <description>To assess the peak plasma concentration of OCZ103-OS after administration on day 1 of first cycle.&#xD;
Amount of OCZ103-OS in serum on day 1 of first cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AE) as a Measure of Safety and Tolerability</measure>
    <time_frame>2 years</time_frame>
    <description>- To assess the number of adverse events in participants due to IV OCZ103-OS in conjunction with standard chemotherapy (mFOLFOX6- or FOLFIRI-contained regimen) in patients with unresectable and locally recurrent or metastatic colorectal cancer requiring second-line chemotherapy from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response (OR)</measure>
    <time_frame>2 years</time_frame>
    <description>- To assess the effect of OCZ103-OS on overall objective response (OR) in subjects with unresectable and locally recurrent or metastatic colorectal cancer treated concurrently with mFOLFOX6 or FOLFIRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DR)</measure>
    <time_frame>2 years</time_frame>
    <description>- To assess the effect of OCZ103-OS on duration of response (DR) in subjects with unresectable and locally recurrent or metastatic colorectal cancer treated concurrently with mFOLFOX6 or FOLFIRI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>OCZ103-OS, mFOLFOX6 or FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCZ103-OS in combination with mFOLFOX6 or FOLFIRI as standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI</intervention_name>
    <description>OCZ103-OS is given in combination with Chemotherapy each cycle</description>
    <arm_group_label>OCZ103-OS, mFOLFOX6 or FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically proven diagnosis of adenocarcinoma of the colon/rectum&#xD;
             with evidence of (1) unresectable and, locally recurrent, or (2) metastatic disease.&#xD;
&#xD;
          2. Failure of first-line therapy(5-Fu-based therapy +/- bevacizumab) for metastatic&#xD;
             colorectal cancer.&#xD;
&#xD;
          3. At least one (1) unidimensionally measurable lesion (on spiral CT scan).&#xD;
&#xD;
          4. 18 years of age or older.&#xD;
&#xD;
          5. ECOG performance status 0, 1 or 2.&#xD;
&#xD;
          6. Serum aspartate transaminase (AST), serum alanine transaminase (ALT), serum alkaline&#xD;
             phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN), or AST,ALT, ALP ≤ 5 x ULN if&#xD;
             liver function abnormalities are due to underlying malignancy&#xD;
&#xD;
          7. Total serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          8. Lipase and amylase within normal limits or abnormal limits but deemed not clinically&#xD;
             significant.&#xD;
&#xD;
          9. Absolute neutrophil count (ANC) ≥ 1500/µL (1.5 x 10e9/L)&#xD;
&#xD;
         10. Platelets ≥ 100,000/µL (100 x 10e9/L)&#xD;
&#xD;
         11. Hemoglobin ≥ 90 g/L&#xD;
&#xD;
         12. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 60 ml/min. The&#xD;
             Cockcroft-Gault formula to be used is as follows:&#xD;
&#xD;
             eCcr=(140-age)x Mass(in kilogram)x Constant/Serum Creatinine(in µmol/L)&#xD;
&#xD;
             Where Constant is 1.23 for men and 1.04 for women.&#xD;
&#xD;
         13. Normal or abnormal ECG. If ECG shows abnormalities, they must be deemed not clinically&#xD;
             significant.&#xD;
&#xD;
         14. Signed and dated Informed Consent Form indicating that the subject (or legally&#xD;
             acceptable representative) has been informed of all the pertinent aspects of the trial&#xD;
             prior to enrollment.&#xD;
&#xD;
         15. Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other trial procedures.&#xD;
&#xD;
         16. Life expectancy, in the opinion of the investigator, &gt; 3 months.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Systolic Blood Pressure &lt;100 mmHg (if deemed clinically significant by the treating&#xD;
             physician).&#xD;
&#xD;
          2. Uncontrolled diabetes, severe renal impairment or pancreatitis.&#xD;
&#xD;
          3. Concomitant therapy with other investigational agents or participation in another&#xD;
             clinical trial within 30 days prior to enrollment.&#xD;
&#xD;
          4. Any of the following conditions: Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2;&#xD;
             atrial fibrillation of any grade; QTc interval &gt; 450 msec for males or &gt; 470 msec for&#xD;
             females or uncontrolled intercurrent illness, e.g. unstable angina; severe coronary&#xD;
             disease, ventricular arrhythmias, bradycardia &lt; 50 bpm; a history of additional risk&#xD;
             factors for torsades de pointes (e.g., heart failure, hypokalemia or family history of&#xD;
             Long QT Syndrome).&#xD;
&#xD;
          5. Active uncontrolled bacterial infection.&#xD;
&#xD;
          6. Concurrent use of drugs that could prolong QT interval (NB: pentamidine is known to&#xD;
             induce torsades de pointes) (see Appendix II: List of drugs that could prolong QT&#xD;
             interval / we also suggest that you refer to the following link:&#xD;
             http://www.azcert.org/medical-pros/drug-lists/bycategory.cfm).&#xD;
&#xD;
          7. Concurrent use of nephrotoxic drugs (depending on the medical health status of the&#xD;
             patient and based on the judgment of the investigator), including but not limited to&#xD;
             aminoglycosides, ampho B, foscarnet and cidofovir.&#xD;
&#xD;
          8. Concurrent use of drugs such as Rifampine and Lamivudine, since these that may be&#xD;
             associated with pancreatitis.&#xD;
&#xD;
          9. Prior malignancy other than colorectal cancer (except for adequately treated carcinoma&#xD;
             in situ of the cervix, non-melanoma skin cancer or localized prostate cancer with&#xD;
             undetectable PSA level) unless the prior malignancy was diagnosed and definitively&#xD;
             treated at least five (5) years previously with no subsequent evidence of recurrence.&#xD;
&#xD;
         10. Clinically significant non-malignant lung disease.&#xD;
&#xD;
         11. History of allergy or hypersensitivity to pentamidine.&#xD;
&#xD;
         12. Pregnancy or breastfeeding. All female patients with reproductive potential must have&#xD;
             a negative pregnancy test (serum or urine) prior to first dose of study medication.&#xD;
&#xD;
         13. Severe acute or chronic medical or psychiatric condition, or laboratory abnormality&#xD;
             that would impart, in the judgement of the investigator, excess risk associated with&#xD;
             trial participation of study drug administration, or which in the judgement of the&#xD;
             investigator, would make the subject inappropriate for entry into this trial.&#xD;
&#xD;
         14. Use of oral anticoagulants (LMWH is acceptable)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Kavan, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benoit Samson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSSS Champlain - Charles-Lemoyne Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Letourneau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luc Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felix Couture, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel-Dieu de Quebec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felix Couture, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSSS Alphonse-Desjardins</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annie Beaudoin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUS-Centre de recherche Etienne-Le Bel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Jolivet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSSS St-Jérome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CSSS Champlain - Charles-Lemoyne Hospital</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSSS Alphonse-Desjardins (CHAU Hotel-Dieu de Levis)</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-St. Luc Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS-Centre de recherche Etienne-Le Bel</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSSS St-Jérome</name>
      <address>
        <city>St-Jérome</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2011</study_first_posted>
  <last_update_submitted>October 20, 2014</last_update_submitted>
  <last_update_submitted_qc>October 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Pentamidine bis(2-hydroxyethanesulfonate)</keyword>
  <keyword>OCZ103-OS</keyword>
  <keyword>Standard of Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

